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Neuroblastoma is a cancer of primitive sympathetic ganglion cells that typically
affects the adrenal glands of children. Significant morbidity and mortality is
associated with neuroblastoma as the third most common pediatric cancer and
high risk patients having less than 50% 5-year survival rates. Further investigation
into the immunosuppressive properties of the neuroblastoma microenvironment
may lead to more favorable patient outcomes. Amyloid precursor-like protein 2
(APLP2) has been associated with a more aggressive tumor phenotype, and
expression may play a role in altering macrophage sub-populations to the tumor-
tolerant M2 phenotype. Furthermore, treatment of neuroblastoma with histone
deacetylation inhibitors (HDACi) has led to increased tumor infiltration of
macrophages.
Hypothesis
Generating APLP2-Knock Out Mouse Model
Introduction
Conclusions and Future Directions
In conclusion, APLP2 expression is associated with the tumor-tolerant M2
macrophage phenotype. Decreasing APLP2 expression may also encourage
anti-tumor M1 polarization, and generating APLP2-KO mouse lines allows for
further characterization of APLP2’s role in macrophage physiology. M344
causes a potent negative effect on Neuro2a viability, and will be further
explored in the context of neuroblastoma’s metastatic potential.
Future directions include investigating the tumor-infiltrating and phagocytic
ability of macrophages in APLP2-KO mice with orthotopically implanted
neuroblastoma. Additionally, HDACi, such as M344, will be investigated for
ability to traffic macrophages to tumors and inhibit tumor migration.
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APLP2-Knock Out Alters Macrophage Polarization
HDACi Treatment Decreases Neuroblastoma ViabilityFigure 1: APLP2 is increased in mouse M2 compared
to M1 macrophages. Bone marrow from femurs and
tibias of euthanized C57BL/6 mice was treated with 50
ng/ml GM-CSF for 7 days, and then polarized for 24
hours. M1 macrophages were generated with 20 ng/mL
IFNγ and 20 ng/mL IL-4 to generate M2.
BB=background band; iNOS=inducible nitric oxide
synthase (indicating M1); ARG=Arginase-1 (indicating
M2)
APLP2 Expression in Polarized Mouse Macrophages
Figure 2: Breeding strategy used to generate macrophage-targeted APLP2-
knockout (KO) C57BL/6 mice. Macrophage-targeted APLP2-KO mice were
generated by breeding mice expressing cre recombinase housed under the Csf1r
promoter, expressed by macrophages and dendritic cells, with mice containing
floxed Aplp2. Genotypes of offspring were verified by PCR for Csf1r-cre and Aplp2.
Figure 4: M344, an HDACi,
causes a dose-dependent
decrease in Neuro2a
viability. Neuro2a cells were
treated with increasing
concentrations of M344 at 24,
48, and 72 hour time points,
and viability was evaluated
through MTT assay. *p<0.05,
**p<0.01, p****<0.0001
Figure 3: CD11b+ CD11c- F4/80+ cells in APLP2-KO mice have increased
ability to polarize to M1 phenotype and decreased M2 polarization. Bone
marrow was extracted from C57BL/6 mice with wild type APLP2 (APLP2 Wild
Type) and mice with APLP2-KO in macrophages (CSF1R APLP2-KO).
Macrophages were cultured in L929 conditioned-media for 7 days then
polarized to M1 (LPS + IFN-γ) or M2 (IL-4) for 3 days prior to flow cytometry
analysis.
APLP2 expression will alter macrophage polarization and ability to initiate anti-
tumor response. Alteration of APLP2 expression and treatment with HDACi will
improve macrophage infiltration and response to neuroblastoma.
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